ON eNews
August 2020
3 Years Into the Journey Approaching each anniversary of me becoming CEO at One Nucleus, I always look back to see where our journey has reached. This past year must rank as one of the strangest in many ways. Through the latter part of 2019 we worked on how to support our members as they focussed on their day job whilst also preparing for Brexit, dealing with distractions such as a General Election and so on. Then, early 2020 lands and nobody was expecting a pandemic and the disruption that comes with it. Through all that however, the sector has remained dynamic, responsive and growing. This in no small part has been down to the excellent leadership in many companies, often invisible outside that organisation and not in the headlines, but critical and first class. Of course, the challenges that were there prior to Covid-19 have not disappeared. Brexit impact still looms, accessing capital is still a challenge that has to be met and creating new healthcare interventions such as therapeutics, diagnostics and technologies is complex. At One Nucleus we have had a strategic review on-going throughout and whilst Covid-19 has certainly adapted how we can support members best going forward, our focus remains firmly on helping our members and wider network where possible to succeed. Your success ultimately means better outcomes for patients. We are all likely be in that position at some stage. Next Steps Against that back-drop, it is as always, a pleasure to welcome you to our monthly newsletter, updating you on our forthcoming activities, the free 3-month extension on membership through Covid-19, our latest survey, current discounts, profiling opportunities available and more. Your Voice Matters I mentioned our latest survey here. This has been prompted by a number of factors that are people related. The recently published UK R&D Roadmap raised some key questions such as how we are going to attract global talent to the UK and how can we make R&D more inclusive. Attracting and retaining the right employees is a frequently raised concern by members, not least with Brexit changes and high growth increasing competition for talent. Much like the data we hold to promote the region and members to global investors and partners, securing data on employment trends and opportunities is equally key in attracting the best. Members are free of course to post vacancies across R&D and operational roles on our website, the jobs page being particularly popular amongst visitors. We also hear talented people are increasingly looking at the purpose and social responsibility of potential employers as a differentiator. Covid-19 has very clearly shown the strong sense of social responsibility within the sector as donated PPE, equipment, collaboration and diverted resources have been seen from companies of all shapes and sizes. How do we harness that for good going forward, encouraging more bright people
2
into our sector to change lives? This will be discussed at our online event with Form the Future on 15th September. Such input from our network enables us to report innovative suggestions back to regional and national policy makers and policy influencers in order to improve mechanisms to support doing the best thing. I am very grateful to those that helped us make ON Helix Digital 2020 such a great success last month. Some excellent panel discussions and presentations, 1-2-1 networking and discussion throughout. Better still, as you’ll see below, it has also given a huge boost to our launching a library of on-demand content for members who wish to review the material they heard or indeed view it for the first time if they missed it. We learned a great deal from delivering the conference and are taking that into our planning of Genesis 2020 also, please see the details about Genesis and how to register below. Beginning, Progress and Success 2020 continues to be a strange kind of year, yet the exciting flow of good news stories and deals coming from our sector gives everyone hope. I am sure that Covid-19 will ultimately be managed, we now have new tools through which to network, entrepreneurs and investors shall see returns, careers will be built and most importantly unmet medical needs will be met. I hope you enjoy the newsletter and linked information and I shall sign off with my favourite Henry Ford quote again “Coming together is a beginning, staying together is progress and working together is success� since it seems more relevant now perhaps than ever. Tony Jones, CEO, One Nucleus
Jobs Survey In order to understand the current levels of recruitment and sourcing of the appropriate employees such that we can inform policymakers, grant bodies and how to provide the best One Nucleus support, we would be grateful if you would complete this short survey. All responses will only be reported in a collated, anonymised form and used to inform our strategy of support. Click here to take the survey.
Supporting ON Members Out of Covid-19 Paramount for One Nucleus since the March lockdown has been to focus on supporting our members through the challenges as best we were able. That has included activities such as the 3 month membership extensions, frequent signposting to guidance updates, dedicated webinars for peer-to-peer sharing of good practice and converting our annual ON Helix event to a fully digital format to enable ideas to be exchanged, members to be showcased and new contacts built. As the situation evolves, we aim to remain nimble in the support we offer our members as they seek to continue adapting, growing and raising their profile to attract investors, partners, clients, talent or all of these. Our next One Nucleus steps to exiting Covid-19 include the following member opportunities: • New members joining will continue to receive the 3 month extension provided they apply on line before 31 August 2020 and pay by the due date in their approval email • Current members renewing will continue to receive one 3 month extension as detailed in the offer in their renewal email • Members will be able to access all recorded ON Helix Digital content free of charge from 10 August 2020 • An updated Annual Review and Directory will be released online in October 2020. For inclusion in the updated edition, membership must be valid at 30 September 2020 • One Nucleus will be showcased at BioEurope 2020, where the updated Annual Review & Directory along with any advertisers within, will be highlighted to the global industry executives anticipated to attend • One Nucleus members can receive a minimum 10% discount on BioEurope registration fees with the convenience of direct online booking using a VIP promotional code specific to One Nucleus. Email info@onenucleus.com for the code. • Normal membership benefits continue to be available including savings, news postings, events, training courses and more
For more information on the above, please email accounts@onenucleus.com
genesis digital 10 December 2020
Registration Open! Retaining flexibility to accommodate these uncertain times, along with learning from our experiences of digital events such as our own ON Helix Digital, we plan to deliver this year’s Genesis Conference digitally at this stage, whilst we wait to hear Government advice for larger gatherings. Deals, Treatments and Patients in the 20s Building on the evolution of the past 19 years, Genesis 2020 will assemble senior executives and decision-makers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders. • High content mix of dedicated parallel tracks interspersed with plenary talks and panels from key opinion leaders • Networking and 1 to 1 meetings with 700+ delegates from across the international Life Science and Healthcare industry • An Exhibitor Workshop area for further technical and business insights • BioNewsRound Award Voting and Final • The Genesis Fringe Events Series
Find out more
Joining the Board of CEBR - Council of European Regions 25 June 2020 was the annual meeting of the Council of European BioRegions – CEBR – and saw the nominations of its new board members elected for three years including our Head of Innovation Support, Aline Charpentier. CEBR is a European membership organisation for bioclusters. It was initiated when the European biotech scene was getting more structured with a steadier flow of investment and company creation across the continent, leading to the development of more cluster organisations and membership groups to support them. These groups felt that there was merit in creating a forum to connect amongst peer groups, exchange good practices and develop joint activities to enhance internationalisation opportunities for their members, and so CEBR was created. 15 years later and an even more mature European biotech industry, CEBR has become a strong network for over 40 bioregions in Europe with a mission to: • Create a European platform for cluster/network development and collaboration. This translates into a deep understanding and knowledge of the different regions involved with enhanced connectivity and data sharing to understand areas of convergence and collaboration opportunities for companies. • Increase visibility of clusters/ bioregions and their contribution to sustainable growth by highlighting and sharing good practices of support mechanisms. • Joint activities to support SME development on international development but also on practical aspects like business development, funding or savings. It’s an exciting time to be joining the CEBR board as there has never been such appetite for working on tangible benefits delivery for members of life sciences clusters across Europe and interest in European connection. It’s also an important message to highlight that European collaborations are essential to our sector and will continue regardless the political context.
Broadening Horizons
Broadening Horizons is a new initiative from Wellcome Trust to support early career researchers in academia with their professional development around awareness of translational career paths by connecting them to peers within industry as mentors. Through four one-to-one meetings and collective events, the scheme will create a future community enabling the effective translation of science and careers form academia to industry. Find out more here.
6
Upcoming Webinars & Digital Events One Nucleus Events 12 August | BioWednesday Online: Joint One Nucleus and #CoffeeBuddies Summer Social - register 02 September | BioWednesday Webinar: How Will Covid-19 Influence Site Selection for Future Trials? - register 15 September | Bringing Purpose to Being the Employer of Choice - register 07 October | BioWednesday Webinar - register 10 December | Genesis Digital 2020 - register
Industry Events 13 August | *MEMBER DISCOUNT* Mental Health Awareness Course - find out more 09-10 Sept | *MEMBER DISCOUNT* Knowledge for Growth Digital Conference - find out more 17 Sept | *MEMBER DISCOUNT* BIA-MHRA Regulatory Innovation Conference 2020 - find out more 22 Sept | CW International Conference (CWIC): At the edge - find out more 23 Sept | CW Technology & Engineering Conference - find out more 24-25 Sept | *MEMBER DISCOUNT* Convergence in Oncology Summit - find out more 06-07 Oct | BioNJ’s 10th Annual BioPartnering Conference - find out more 26-29 Oct | *MEMBER DISCOUNT* BIO-Europe 2020 Digital - find out more
Members, get in touch if you would like your webinar/event promoted on our website and social channels: laurahicks@onenucleus.com
Corporate Patron
Corporate Sponsors
Member Articles An Introduction to Patent Due Diligence A patent due diligence analysis can be an important and cost-effective tool for your company. It helps you determine the value of your own patent portfolio, including whether you can monetize your patents through licensing, enforcement or divestment. Conversely, it allows you to assess and mitigate the infringement risks posed by a competitor’s patents or the patents of another party, such as a Non-Practicing Entity (NPE). Diligence, for example, can guide your strategy for responding to a cease-and-desist letter from an NPE and can mitigate your damages exposure against a finding of willful infringement. This post is part of a longer series designed to answer questions related to patent due diligence, when to do the analysis, what forms it may take, and what to look for in each step. Here, we provide a general overview of what patent due diligence is and various practical scenarios where it may be helpful. Q1: What is Patent Due Diligence in the Patent Context?
Continue reading here.
DIT: Biopharmaceutical Virtual Mission, India 29th and 30th September 2020 Why attend: • Chance to interact with key stakeholders and influencers from the Indian biopharmaceutical industry • Hear from high profile speakers from reputed organizations on key issues/ opportunities in the industry from both UK and India • Part of a strong delegation to showcase UK strength in innovation in Biopharma • Focussed 1:1 meetings with potential buyers/ partners • Dedicated support from DIT network
Find out more here.